These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36212444)

  • 1. Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma.
    Lorusso D; Danesi R; Locati LD; Masi G; De Giorgi U; Gadducci A; Pignata S; Sabbatini R; Savarese A; Valabrega G; Zamagni C; Colombo N
    Front Oncol; 2022; 12():979519. PubMed ID: 36212444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
    Makker V; Taylor MH; Oaknin A; Casado Herraez A; Orlowski R; Dutta L; Ren M; Zale M; O'Malley DM
    Oncologist; 2021 Sep; 26(9):e1599-e1608. PubMed ID: 34190370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
    Colombo N; Lorusso D; Monk BJ; Slomovitz B; Hasegawa K; Nogueira-Rodrigues A; Zale M; Okpara CE; Barresi G; McKenzie J; Makker V
    Oncologist; 2024 Jan; 29(1):25-35. PubMed ID: 37523661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis.
    Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N
    Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
    Makker V; Rasco D; Vogelzang NJ; Brose MS; Cohn AL; Mier J; Di Simone C; Hyman DM; Stepan DE; Dutcus CE; Schmidt EV; Guo M; Sachdev P; Shumaker R; Aghajanian C; Taylor M
    Lancet Oncol; 2019 May; 20(5):711-718. PubMed ID: 30922731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
    Motzer R; George S; Merchan JR; Hutson TE; Song X; Perini RF; Xie R; Bapat U; Puente J
    Oncologist; 2023 Jun; 28(6):501-509. PubMed ID: 36866412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma.
    Grünwald V; Larkin J; Puente J; Bedke J; Porta C
    Clin Genitourin Cancer; 2024 Apr; 22(2):394-401. PubMed ID: 38218660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
    Ikeda M; Kobayashi M; Tahara M; Kaneko S
    Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
    Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
    Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
    Mo DC; Luo PH; Huang SX; Wang HL; Huang JF
    Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma.
    Walker CA; Spirtos AN; Miller DS
    Expert Rev Anticancer Ther; 2023 Apr; 23(4):361-368. PubMed ID: 36944439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib Plus Pembrolizumab versus Doxorubicin for Advanced or Recurrent Endometrial Cancer with Short Treatment-Free Intervals Following First-Line Carboplatin Plus Paclitaxel.
    Wang SJ; Chen HH; Sun L; Shih YH; Lu TF; Chen YF; Fan CT; Hsu ST; Liu CK; Hwang SF; Lu CH
    J Clin Med; 2024 Sep; 13(19):. PubMed ID: 39407730
    [No Abstract]   [Full Text] [Related]  

  • 15. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
    Kitano S; Fujiwara Y; Shimizu T; Iwasa S; Yonemori K; Kondo S; Shimomura A; Koyama T; Ebata T; Ikezawa H; Hayata N; Minoshima Y; Miura T; Kubota T; Yamamoto N
    Cancer Chemother Pharmacol; 2022 Dec; 90(6):523-529. PubMed ID: 36289094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report.
    Fellouah M; Auclair MH; Fortin S; Berdugo J; de Guerké L
    Gynecol Oncol Rep; 2023 Oct; 49():101235. PubMed ID: 37636497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case Report: Hypertriglyceridemia-Induced Pancreatitis after Lenvatinib and Pembrolizumab Use.
    Sultan K; Khan Z; Saadat S
    Case Rep Oncol; 2024; 17(1):311-316. PubMed ID: 38390453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit.
    Wirth LJ; Durante C; Topliss DJ; Winquist E; Robenshtok E; Iwasaki H; Luster M; Elisei R; Leboulleux S; Tahara M
    Oncologist; 2022 Jul; 27(7):565-572. PubMed ID: 35482606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
    Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
    Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.